LIGAND PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIGAND PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $50.47M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $33.38M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $28.00M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $29.27M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $38.19M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $21.62M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $19.52M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $29.65M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $21.19M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $17.70M | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $268.09M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $167.13M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $131.31M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $50.38M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $59.22M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $50.13M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $36.52M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $56.40M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $59.69M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $78.85M | Feb 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.03M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $52.15M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | ($17.49M) | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $404.0K | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | ($895.0K) | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | ($15.39M) | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | ($5.42M) | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $13.72M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $30.73M | Feb 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($22.61M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $11.94M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $3.04M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $103.85M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $37.50M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $807.08M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $163.73M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $68.08M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $43.89M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.18M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $21.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $24.54M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $9.20M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $9.24M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $8.47M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $9.18M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $8.15M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $7.43M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $7.48M | Feb 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $97.05M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $49.58M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $137.85M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $78.80M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $54.59M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($29.34M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $194.06M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $88.57M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $60.73M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $452.0K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.82M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $3.52M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $17.92M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $8.76M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $4.46M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $2.55M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $887.0K | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.16M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.85M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $941.77M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $787.22M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $762.67M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.30B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.36B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.49B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.26B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $671.02M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $601.59M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $543.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $111.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $86.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $165.18M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $476.43M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $652.76M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $727.68M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $699.89M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $252.37M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $230.73M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $830.44M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $700.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $597.49M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $821.16M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $709.53M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $767.23M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $560.91M | Feb 28, 2022 |
| FY2018 | Dec 31, 2017 | $399.79M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $341.29M | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.54M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $105.25M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $103.37M | Feb 28, 2025 |
| FY2024 | Dec 31, 2022 | $0 | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $105.67M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $189.66M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $95.23M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $86.65M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $85.96M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $72.21M | Mar 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $608.09M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $498.98M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $503.02M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $450.86M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $449.09M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $391.95M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $400.11M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($229.20M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($400.92M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($431.13M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.93M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $72.31M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $22.95M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $45.01M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $19.52M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $47.62M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $71.54M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $117.16M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $20.62M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $18.75M | Mar 1, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $27.50M | Mar 14, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.77M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 19.11M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 17.56M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 16.95M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 16.77M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 16.08M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 16.82M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 20.77M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 21.15M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 20.91M | Mar 1, 2018 |